Considering tumor heterogeneity, the tumor microenvironment, and the multiple actions of other oncogenes alongside KRAS mutation, applying our metabolomic profiles to an organoid system established from patients with pancreatic cancer, rather than a two-dimensional in vitro culture system, may offer greater clinical utilities. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.